Live Breaking News & Updates on Avadel Pharmaceuticals Plc|Page 2
Stay updated with breaking news from Avadel pharmaceuticals plc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day ....
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive daytime sleepiness in adult patients with narcolepsy. Jazz says Avadel's Lumryz is an extended-release reformulation of its high sodium oxybate product Xyrem for narcolepsy. Jazz argues that the approval was unlawful and violates the orphan drug exclusivity of Xywav. In an SEC filing, Jazz alleges that ....
Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Rating) has been assigned an average rating of “Buy” from the seven analysts that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in […] ....
Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Rating) have received an average recommendation of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last […] ....